GDD-3898 is under clinical development by Lipidio Pharmaceuticals and currently in Phase II for Dermatological Disorders. According to GlobalData, Phase II drugs for Dermatological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the GDD-3898 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GDD-3898 overview

GDD-3898 is under development for the treatment of nonalcoholic fatty liver disease, non-alcoholic steatohepatitis, Prader-Willi syndrome, antipsychotic drug-induced weight gain (AIWG), acne vulgaris and sebaceous hyperplasia. The drug candidate acts by targeting stearoyl-CoA desaturase (SCD-1). It is administered through topical route.

Lipidio Pharmaceuticals overview

Lipidio Pharmaceuticals is a healthcare company that focuses on advancing a molecule to treat diseases associated with excess body fat. It includes non-alcoholic steatohepatitis, Prader-Willi syndrome, and antipsychotic drug-induced weight gain. Lipidio Pharmaceuticals is headquartered in San Diego, California, the US.

For a complete picture of GDD-3898’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.